The Signal: A2 Biotherapeutics

Published
Jun 16, 2026 4:44AM EDT
The Signal
About This Series

The Signal is Nasdaq’s editorial business news series, showcasing the leading companies that are moving markets. Episodes feature candid conversations with founders and CEOs across industries, unpacking the latest technologies, innovations, and applications that are driving change across the economy.

A2 Biotherapeutics is advancing precision cell therapies designed to more safely target cancer. During this discussion, President & CEO Jim Robinson discusses the company’s proprietary Tmod™ platform, recent clinical progress, and the opportunity to unlock new treatments for solid tumors. He also shares how A2 is working to bring greater precision, safety, and scalability to the next frontier of cancer care.

Transcripts

No transcript available